November 22, 2021In a recent study, George Mason Ä¢¹½AV Associate Professor Hong Xue, PhD and colleagues evaluated the impact of ending market exclusivity for brand-name statin drugs. The first study to comprehensively assess the economic impact of generic competition for statins found that ending market exclusivity for statins saves U.S. $12 billion and individuals nearly $1,000 annually.
